You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Enhanced CRISPR gene editing in pluripotent stem cells using carbon nanotube arrays
SBC: Advanced Gene Transfer Company, Inc. Topic: NIGMSABSTRACT The goal of the proposed studies is to improve the efficiency of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing in human pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Currently, CRISPR/Cas9 shows great potential for targeted gene editing, but remains challenging in PSCs due to their b ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
SBC: BIOSPUTNIK LLC Topic: NHLBI1 ABSTRACT2 Tuberous sclerosis (TS), also called tuberous sclerosis complex, is a rare, multi-systemic genetic and often life-3 threatening disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys,4 heart, eyes, lungs, and skin. Lymphangioleiomyomatosis (LAM) is a TS-related tumor-like disorder. Both occur5 as a consequence of an inherited or sporadic mu ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Discovery of therapeutic nanobodies targeting brain TNF-α for the treatment of Alzheimer Disease
SBC: NANONEWRON LLC Topic: NIAProject SummarySporadic, late onset Alzheimer disease (LOAD) is the most common form of aging-dependent neurodegenerative disorder. LOAD is associated with deposition of extracellular amyloid plaques and intra-neuronal neurofibrillary tangles (NFT), formed by Aβ peptides and phosphor- tau, respectively, in the central nervous system (CNS). Although there is strong consensus that toxic forms of AΠ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B
SBC: NECTAGEN INC Topic: NIAIDInfection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based digital health navigation program for colorectal cancer screening
SBC: DIGITAL HEALTH NAVIGATION SOLUTIONS, INC. Topic: 102Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or e ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing RNA therapeutics for rare neurodevelopmental disorders
SBC: Dayi Therapeutics, Inc. Topic: NICHDPROJECT SUMMARY Developing RNA therapeutics for rare neurodevelopmental disorders Monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration
SBC: CRIMSON BIOPHARM INC Topic: NCIPROJECT SUMMARY The epidermal growth factor receptor (EGFR) gene is mutated and/or amplified in majority of primary glioblastoma (GBM). While EGFR-mutant GBM cancer cells are dependent on EGFR signaling for survival, numerous small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to show efficacy in this disease. There are two main reasons for these failures: i) Many of these EGFR-TKIs ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD
SBC: Aviara Pharmaceuticals, Inc. Topic: 300Inflammatory bowel disease (IBD) is comprised mainly of Crohn’s Disease (CD) and Ulcerative Colitis (UC), and is characterized by a chronic non-resolving inflammatory response in the intestinal mucosa. Although the exact etiology is unknown, dysbiosis, genetic, environmental, and immunologic factors are all thought to play roles in this multifactorial disease. There are no cures, and in most cas ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Production of radiometal-based radiopharmaceuticals at a clinical scale via droplet-scale radiochemistry
SBC: DropletPharm Inc. Topic: NIBIBPROJECT SUMMARY Despite the enormous value of radiopharmaceuticals for imaging and therapy in clinical nuclear medicine, and for research and drug development, the production of these compounds remains very expensive because of the need for complex, capital-intensive equipment and infrastructure (i.e., hot cells, stack monitor, radiosynthesizer, and a suite of QC testing equipment) at each site. F ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Epigenetic Modifiers to treat Photoreceptor Degenerations
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract:The overall goal of Skyran Biologics is to develop powerful topical therapeutics to combat retinal degenerative diseases. In the course of our studies on epigenetic regulation of retinal development we have defined ways in which histone modifications can lock genes encoding these mechanisms into inactive, condensed chromatin. We found a number of drugs that partially reverse chromatin con ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health